Cargando…
Evaluation of survival extrapolation in immuno-oncology using multiple pre-planned data cuts: learnings to aid in model selection
BACKGROUND: Due to limited duration of follow up in clinical trials of cancer treatments, estimates of lifetime survival benefits are typically derived using statistical extrapolation methods. To justify the method used, a range of approaches have been proposed including statistical goodness-of-fit...
Autores principales: | Bullement, Ash, Willis, Anna, Amin, Amerah, Schlichting, Michael, Hatswell, Anthony James, Bharmal, Murtuza |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204248/ https://www.ncbi.nlm.nih.gov/pubmed/32375680 http://dx.doi.org/10.1186/s12874-020-00997-x |
Ejemplares similares
-
What is the Impact of the Analysis Method Used for Health State Utility Values on QALYs in Oncology? A Simulation Study Comparing Progression-Based and Time-to-Death Approaches
por: Hatswell, Anthony J., et al.
Publicado: (2020) -
Cost Effectiveness of Avelumab for Metastatic Merkel Cell Carcinoma
por: Bullement, Ash, et al.
Publicado: (2019) -
A Systematic Review of Methods to Incorporate External Evidence into Trial-Based Survival Extrapolations for Health Technology Assessment
por: Bullement, Ash, et al.
Publicado: (2023) -
Estimating Lifetime Benefits Associated with Immuno-Oncology Therapies: Challenges and Approaches for Overall Survival Extrapolations
por: Ouwens, Mario J. N. M., et al.
Publicado: (2019) -
Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation
por: Gibson, Eddie, et al.
Publicado: (2017)